Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 286 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR 10 Things About You That Change When You Lose Your Parents March 29, 2019 Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... June 7, 2023 Young Man’s “Water You Can Eat” Invention for His Grandma with... July 8, 2020 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Load more HOT NEWS Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... Doctors Want Breast Cancer Warning Label Put On Cheese Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has...
